WASHINGTON (Reuters) - Slower tumor growth in kidney cancer patients taking Pfizer Inc's drug Inlyta in trial was driven by a small subset of patients who are likely rare in the United States, Food ...

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma. Bavencio ...

A panel advising the European Union's drug regulator voted to endorse Pfizer's (PFE - News) Inlyta drug to treat kidney cancer. The FDA approved Inlyta for use in the U.S. in January. The committee ...

The drug-pricing agreement Pfizer struck with the Trump administration in September could generate up to $280 million in annual savings for state Medicaid programs, according to an analysis published ...

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer. Treatment with Keytruda (pembrolizumab) combined with Inlyta (axitinib) ...

Five years after scoring an FDA approval to treat newly diagnosed advanced kidney cancer, the combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta has failed on the overall survival endpoint of a ...

(Reuters) - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone ...

Pfizer PFE comprises six business units — Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Oncology sales are likely to have risen in the first quarter, ...